Stroke induces cell necrosis and triggers inflammation as manifested by pro-inflammatory cytokine production, glial reactivity and leukocyte infiltration. The acute inflammatory reaction is thought to exacerbate brain damage. Some anti-inflammatory treatments are protective in experimental animal models of stroke. However, efficacy of these treatments has not yet been demonstrated in the clinical setting. Peripheral immune cells can gain access to the brain parenchyma and interact with resident cells to affect tissue responses and contribute to clearance of the damaged tissue. Also, during the days that follow stroke, the inflammatory response is attenuated by immunomodulatory cells such as regulatory T (Treg) (Liesz et al., 2009 ) or B (Ren et al., 2011 lymphocytes that produce the anti-inflammatory cytokine IL-10. Macrophages, and probably microglia as well, can be activated to acquire different phenotypes depending on the environment. In vitro, two prototypical phenotypes known as M1 and M2 develop after exposure to the pro-inflammatory mediators LPS/IFN-c, and IL-4, respectively. The situation is more complex in vivo where the variety of phenotypes that macrophages and microglia can acquire in disease conditions are much greater than the archetypal M1/M2 phenotypes induced in vitro upon cytokine stimulation. Typically, cytokines released by polarized T helper type 2 (Th2) lymphocytes induce alternative M2 macrophage polarization that contributes to resolution of inflammation and tissue repair. The expression of markers of alternative polarization has been reported in microglia/macrophages after brain ischemia (Perego et al., 2011) .
The cytokine interleukin-33 (IL-33) signals through the IL-1 receptor-related protein ST2 that is expressed by Th2 but not Th1 cells (Xu et al., 1998) . IL-33 induces the production of Th2-associated cytokines, including IL-4, IL-5, and IL-13 (Schmitz et al., 2005) , and facilitates immunomodulation by expanding Treg cells (Turnquist et al., 2011) . In this issue of Brain, Behavior and Immunity, Korhonen et al. report the effects of systemic administration of IL-33 in a mouse model of stroke (Korhonen et al., 2015) . These scientists induced focal brain ischemia by permanent occlusion of the middle cerebral artery in mice and administered IL-33 i.p. or i.v. either before or immediately after ischemia. Regardless of treatment regimen, IL-33 reduced infarct volume at 24 h and ameliorated the neurological deficits during the week following stroke. These beneficial effects of IL-33 did not seem to be mediated by Treg given that they were not abrogated by treatment with a blocking antibody against CD25. However, IL-33 treatment reduced splenic TNF-a while it increased the production of IL-4 in the spleen and the peripheral ischemic brain tissue. Notably, administration of a blocking antibody against IL-4 one hour prior to ischemia partially prevented the protective effect of IL-33, suggesting that it was, at least in part, mediated by IL-4. Given that IL-4 promotes the alternative polarization of macrophages and microglia, Korhonen et al. went on to examine the expression of the M2 marker Arginase-1 (Arg1) in brain tissue. They found increased expression of Arg-1, suggesting that IL-33 promoted the alternative activation of macrophages/microglia in ischemic tissue, thus counteracting the inflammatory response.
But which cellular target of IL-33 is responsible for the beneficial effect of IL-4 in stroke? It has been previously reported that IL-33 acts as a danger signal and increases the production of TNF-a after LPS stimulation of macrophages (Espinassous et al., 2009) . The current study (Korhonen et al., 2015) found that IL-33 induced astrocyte activation as assessed by an increase in the production of IL-6 in cultured astrocytes. However, this was in contrast to in vivo IL-33 treatment that attenuated the astroglial reaction induced by ischemia. Furthermore, IL-33 did not prevent death of cultured neurons exposed to oxygen and glucose deprivation. Together, these findings suggested that the protective effect of IL-33 in vivo was not mediated by a direct action on neurons or glia. Instead, the results suggested that the beneficial effects could be mediated by T-cells since they released IL-4 after exposure to IL-33 and the conditioned medium of IL-33-treated T cells exerted anti-inflammatory effects in cultured astroglia.
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